Delayed Australian S.E. 09:29:42 2024-05-20 pm EDT 5-day change 1st Jan Change
0.009 AUD 0.00% Intraday chart for Memphasys +28.57% -25.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Memphasys' Felix System 'Outperforms' Widely Used Sperm Preparation Methods in Japanese Trial; Shares Up 13% MT
Memphasys Secures Additional Order for Fertility Device System in Japan; Shares Jump 9% MT
Memphasys Completes Trial of Animal Fertility System MT
Memphasys' Entitlement Offer Undersubscribed MT
Memphasys Signs Distribution Deals for Fertility System; Shares Jump 8% MT
Memphasys Receives AU$1.3 Million R&D Tax Rebate MT
India Records 10 More Live Births Using Memphasys' Fertility Device MT
Vitrolife Japan Places Initial Order for Memphasys' Felix System MT
Memphasys Signs Exclusive Japan Distribution Deal for Reproductive Device; Shares Surge 23% MT
Memphasys Secures Two New Australian Patents for the Felix System MT
Study Reveals Advantage of Memphasys' Felix System in Recovering Sperm Post Cryopreservation; Shares Jump 19% MT
Memphasys Sells Units of Sperm Separator Device in Japan; System Achieves First Live Birth; Shares Jump 6% MT
Memphasys Validates Efficacy of Fertility Device MT
Memphasys Secures Court Clearance, to Start Capital Raise MT
Memphasys' Felix System Found to be Superior to IVF Procedure DGC MT
Memphasys Appoints Nonexecutive Chair; Shares Fall 3% MT
Memphasys' Horse Fertility Diagnostic Device Achieves Up to 90% Accuracy Rate MT
Memphasys Receives ISO 13485 Compliance for Quality Management System MT
Memphasys to Start Clinical Trial for Bio-Separator Device; Shares Jump 8% MT
Memphasys Completes Field Trial for Horse Fertility Diagnostic Device MT
Memphasys Makes Maiden Sale of Sperm Separating Device MT
Memphasys : Receives $1 Million R&D Tax Refund; Secures China Sperm Separation Patent MT
Memphasys : Advances Development of Animal Reproductive Device MT
Memphasys' : Upgraded Felix Device Passes Internal Verification MT
Memphasys : Secures $2.3 Million Via Convertible Bond Issue MT
Chart Memphasys
More charts
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. MEM Stock
  4. News Memphasys
  5. Memphasys Secures Court Clearance, to Start Capital Raise
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW